Digital phenotyping adherence, feasibility, and tolerability in outpatients with schizophrenia.
Ambulatory assessment
Clinical Trials
Ecological momentary assessment
Experience sampling
Psychosis
Journal
Journal of psychiatric research
ISSN: 1879-1379
Titre abrégé: J Psychiatr Res
Pays: England
ID NLM: 0376331
Informations de publication
Date de publication:
06 2021
06 2021
Historique:
received:
09
12
2020
revised:
19
04
2021
accepted:
25
04
2021
pubmed:
9
5
2021
medline:
6
7
2021
entrez:
8
5
2021
Statut:
ppublish
Résumé
Digital phenotyping has potential for use as an objective and ecologically valid form of symptom assessment in clinical trials for schizophrenia. However, there are critical methodological factors that must be addressed before digital phenotyping can be used for this purpose. The current study evaluated levels of adherence, feasibility, and tolerability for active (i.e., signal and event contingent ecological momentary assessment surveys) and passive (i.e., geolocation, accelerometry, and ambulatory psychophysiology) digital phenotyping methods recorded from smartphone and smartband devices. Participants included outpatients diagnosed with schizophrenia (SZ: n = 54) and demographically matched healthy controls (CN: n = 55), who completed 6 days of digital phenotyping. Adherence was significantly lower in SZ than CN for active recordings, but not markedly different for passive recordings. Some forms of passive recordings had lower adherence (ambulatory psychophysiology) than others (accelerometry and geolocation). Active digital phenotyping adherence was predicted by higher psychosocial functioning, whereas passive digital phenotyping adherence was predicted by education, positive symptoms, negative symptoms, and psychosocial functioning in people with SZ. Both groups found digital phenotyping methods tolerable and feasibility was supported by low frequency of invalid responding, brief survey completion times, and similar impediments to study completion. Digital phenotyping methods can be completed by individuals with SZ with good adherence, feasibility, and tolerability. Recommendations are provided for using digital phenotyping methods in clinical trials for SZ.
Identifiants
pubmed: 33964681
pii: S0022-3956(21)00249-1
doi: 10.1016/j.jpsychires.2021.04.022
pmc: PMC8192468
mid: NIHMS1699641
pii:
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
436-443Subventions
Organisme : NIMH NIH HHS
ID : R21 MH112925
Pays : United States
Informations de copyright
Copyright © 2021 Elsevier Ltd. All rights reserved.
Références
Schizophr Res. 2020 Feb;216:56-68
pubmed: 31874743
Schizophr Bull. 2012 May;38(3):396-404
pubmed: 22302902
Schizophr Bull. 2012 May;38(3):405-13
pubmed: 22130904
NPJ Digit Med. 2020 Apr 14;3:55
pubmed: 32337371
J Dual Diagn. 2012 Oct;8(4):305-314
pubmed: 23459025
Psychol Med. 2001 Apr;31(3):489-98
pubmed: 11305857
World Psychiatry. 2019 Feb;18(1):103-104
pubmed: 30600611
Schizophr Res. 2013 Apr;145(1-3):120-4
pubmed: 23402693
Psychol Assess. 2019 Mar;31(3):304-317
pubmed: 30802116
Int J Methods Psychiatr Res. 2009;18(1):48-57
pubmed: 19195050
Psychiatr Rehabil J. 2014 Dec;37(4):316-320
pubmed: 25496200
Clin Psychol Sci. 2020 May 1;8(3):555-568
pubmed: 33758684
Schizophr Bull. 2021 Jan 23;47(1):44-53
pubmed: 32467967
Neuropsychopharmacology. 2021 Jan;46(1):45-54
pubmed: 32679583
Psychiatry Res. 2014 Dec 15;220(1-2):89-95
pubmed: 25124684
J Abnorm Psychol. 2019 Oct;128(7):723-734
pubmed: 31464449
Schizophr Bull. 2020 Feb 26;:
pubmed: 32103266
J Abnorm Psychol. 1976 Aug;85(4):374-82
pubmed: 956504
Schizophr Bull. 2014 Nov;40(6):1244-53
pubmed: 24609454
Schizophr Bull. 2000;26(4):847-54
pubmed: 11087017
CNS Neurosci Ther. 2011 Dec;17(6):612-9
pubmed: 21073668
Am J Psychiatry. 2008 Feb;165(2):203-13
pubmed: 18172019
Schizophr Bull. 2011 Mar;37(2):300-5
pubmed: 20558531
Schizophr Bull. 1987;13(2):261-76
pubmed: 3616518
Psychol Med. 2018 Oct;48(14):2337-2345
pubmed: 29361997
Schizophr Res. 2018 Jul;197:67-68
pubmed: 29338959
Assessment. 2020 Sep 10;:1073191120957102
pubmed: 32909448
Psychiatr Serv. 2016 May 1;67(5):558-61
pubmed: 26695497
JAMA. 2017 Oct 3;318(13):1215-1216
pubmed: 28973224
Schizophr Bull. 2020 Dec 1;46(6):1596-1607
pubmed: 32851401
Schizophr Bull. 2020 Feb 26;46(2):242-251
pubmed: 31504955
Clin Psychol Sci. 2018 Mar;6(2):271-279
pubmed: 29732243
PLoS One. 2014 Jun 26;9(6):e100935
pubmed: 24967710
Schizophr Res. 2019 Jun;208:167-172
pubmed: 30940400
NPJ Digit Med. 2020 Mar 11;3:33
pubmed: 32195368
Am J Psychiatry. 2002 Mar;159(3):443-9
pubmed: 11870009
Schizophr Bull. 2016 May;42(3):712-22
pubmed: 26834027
J Abnorm Psychol. 2008 Feb;117(1):143-53
pubmed: 18266492
Neuropsychopharmacology. 2018 Jul;43(8):1660-1666
pubmed: 29511333
Schizophr Res. 2007 Jul;93(1-3):253-60
pubmed: 17490858
J Abnorm Psychol. 2020 Jan;129(1):56-63
pubmed: 31868388
Arch Gen Psychiatry. 1975 Mar;32(3):343-7
pubmed: 1115575
NPJ Digit Med. 2019 Nov 8;2:108
pubmed: 31728415
Neuropsychopharmacology. 2016 Jun;41(7):1691-6
pubmed: 26818126
Schizophr Bull. 2008 May;34(3):507-14
pubmed: 17932087
Schizophr Res. 2020 Jun;220:141-146
pubmed: 32247747
J Abnorm Psychol. 2017 Jan;126(1):96-105
pubmed: 27893230
J Med Internet Res. 2019 Dec 6;21(12):e14475
pubmed: 31808748
World Psychiatry. 2020 Feb;19(1):114-115
pubmed: 31922662